At day 4 post-treatment with the anti-HER2 targeted therapy, trastuzumab, BT-474 tumors showed a significant decrease in the percent tumor volume of the LV-HC habitat (p < 0.01) and corresponding increase in the percent tumor volume of the HV-HC habitat (p = 0.02) from baseline. This evidence concerns the gene ERBB2 and neoplasm.